The Phase I Nerofe (dTCApFs) human trial summary has been published in the Molecular and Clinical Oncology Journal.
In this trial Nerofe was found to be safe and well‑tolerated, and potentially efficacious as an anti-cancer agent.
The Phase I Nerofe (dTCApFs) human trial summary has been published in the Molecular and Clinical Oncology Journal.
In this trial Nerofe was found to be safe and well‑tolerated, and potentially efficacious as an anti-cancer agent.
ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John […]